$-0.04 EPS Expected for Can-Fite BioPharma Ltd. (CANF) | Thorold News – Thorold News

Analysts expect Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) to report $-0.04 EPS on March, 22.They anticipate $0.02 EPS change or 33.33 % from last quarter’s $-0.06 EPS. The stock decreased 0.88% or $0.0099 during the last trading session, reaching $1.1201. About 77,484 shares traded. Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) has declined 29.14% since March 17, 2018 and is downtrending. It has underperformed by 33.51% the S&P500.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company has market cap of $25.74 million. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It currently has negative earnings. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction.

More notable recent Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) news were published by: Businesswire.com which released: “Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year – Business Wire” on September 04, 2018, also Businesswire.com with their article: “Can-Fite BioPharma CEO Letter to Shareholders – Business Wire” published on January 24, 2019, Profitconfidential.com published: “IGC Stock Forecast: Is IGC Attracting Big Beverage Partnership with CBD Energy Drink? – Profit Confidential” on October 03, 2018. More interesting news about Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) were released by: Streetinsider.com and their article: “Synthetic Biologics (SYN) Announces 1-for-35 Reverse Stock Split – StreetInsider.com” published on August 01, 2018 as well as Businesswire.com‘s news article titled: “Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert – Business Wire” with publication date: November 20, 2018.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Source: https://whatsonthorold.com/2019/03/17/0-04-eps-expected-for-can-fite-biopharma-ltd-canf-2/


Recommended


What is CBD Oil

CBD Benefits

cbd oil effects